Vote Scores
Filings read through

Summit Therapeutics Inc.: how funds voted at the meeting of 10 Jun 2026

Ticker
SMMT
Meeting
Season
year to 30 June 2026
Filers reporting
306
Ballot items
4

306 filers on Form N-PX reported votes at the Summit Therapeutics Inc. meeting of 10 Jun 2026. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    9 nominees. 73.3% of the reported votes are for. 69 filers withheld from or voted against at least one nominee.

    1,656 vote records from 92 filers. 27 of the 88 filers that marked the item voted against management. 4 filers gave no management mark.

    • Positions of 25 fund families
    • For 18
    • Abstain or withhold 7
    • Against management 7
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    438 vote records from 305 filers. 205 of the 285 filers that marked the item voted against management. 20 filers gave no management mark.

    • Positions of 34 fund families
    • For 3
    • Against 30
    • Split or no vote 1
    • Against management 30
  3. Item 3: Audit-related items (auditor ratification)

    184 vote records from 92 filers. 0 of the 88 filers that marked the item voted against management. 4 filers gave no management mark.

    • Positions of 25 fund families
    • For 25
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    197 vote records from 95 filers. 72 of the 91 filers that marked the item voted against management. 4 filers gave no management mark.

    • Positions of 25 fund families
    • For 5
    • Against 20
    • Against management 20

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Summit Therapeutics Inc., meeting of 10 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinAgainst, against managementNo report
AllspringSplitNo report
BlackRock and iSharesAgainst, against managementFor
BNY MellonAgainst, against managementFor
Charles SchwabAgainst, against managementFor
Columbia ThreadneedleAgainst, against managementFor
DimensionalAgainst, against managementFor
DWSAgainst, against managementNo report
EquitableAgainst, against managementFor
FidelityForFor
First TrustAgainst, against managementNo report
Goldman SachsAgainst, against managementFor
Guggenheim and RydexAgainst, against managementFor
InvescoAgainst, against managementFor
J.P. MorganAgainst, against managementFor
Jackson National fundsAgainst, against managementFor
John Hancock and ManulifeAgainst, against managementFor
Lincoln FinancialAgainst, against managementFor
MassMutualForNo report
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementFor
Natixis and Loomis SaylesAgainst, against managementNo report
Neuberger BermanAgainst, against managementNo report
Northern Trust and FlexSharesAgainst, against managementFor
Nuveen and TIAAForFor
Pacific Life fundsAgainst, against managementFor
PGIM and PrudentialAgainst, against managementNo report
PrincipalAgainst, against managementFor
ProShares and ProFundsAgainst, against managementFor
Russell InvestmentsAgainst, against managementNo report
SEIAgainst, against managementFor
State Street and SPDRAgainst, against managementFor
T. Rowe PriceAgainst, against managementFor
VanguardAgainst, against managementFor
VoyaAgainst, against managementFor

Questions

How many filers reported votes at the Summit Therapeutics Inc. meeting?
306 Form N-PX filers reported votes at the meeting of 10 Jun 2026. On say-on-pay, 205 of 285 filers that marked the item voted against management (71.9%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Summit Therapeutics Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Summit Therapeutics Inc. with a meeting date within three days of 10 Jun 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .